throbber
HI
`
`53706
`
`MADISON
`1215 H DAYTON ST
`UNIV HISCONSIN
`GEOLOGY GEOPHY LIB
`00000905836SC Ol/03/92N9119
`17
`************ CAR-RT SORT ** CR03
`
`Par Pharm., Inc.
`Exhibit 1029
`Page 001
`
`

`
`AMERICAN
`AssociATION FOR THE
`. ADVANCEMENT OF
`SCIENCE
`
`SciENCE
`
`ISSN 0036-8075
`!0 MAY 1991
`VOLUME 252
`NuMBER 5007
`
`755 This Week in Science
`
`M DtJni.JQij- 757 Technology for America's Future
`Letters
`
`763 Science in the Persian Gulf: T. M. BoYCE • Math Problems: T. M. MuRPHY;
`M. W. LEVINE; R. D. HANsoN; C. B. HATFIELD; D. E. KosHLAND, JR. • Energy
`Savings: A. B. LoviNS; G. M. BARNWELL • EPA Committee: M. E. O'CONNOR •
`Crystal Stmcture of Bee-Venom Phospholipase A2 : Correction: D. L. ScoTT,
`Z. OTWINOWSKI, M. H . GELB, P. B. SIGLER • Membrane-Bound Phosphotyrosine
`Phosphatases: A. F. WILLIAMS
`
`ScienceSco e
`News & Con1ment
`
`Research News
`
`Articles
`
`Research Articles
`
`767 Sweeping overhead rates under the mg; gambling with Poker Flat science; etc.
`
`768 Baltimore Throws in the Towel • David Baltimore's Mea Culpa
`771 The True Source of HIV?
`772 Science Under Wraps in Prince William Sound
`773 Science Academy Elects New Members
`774 Briifrngs: Hidden Costs of the Space Station • A Big Gift from Big Oil • A Billion
`Bucks for Materials • Congressional Day • Ten Years for the Brain • Cuban AIDS
`Control • Biotechnology Execs Earn More • Correction
`
`776 Engineering Dogma Gives Way to Chaos • Flying High with Chaos Control
`778 A New Ball Game in Nuclear Physics
`779 How Peptide Hormones Get Ready for Work
`781 Praying Mantises Play Top Gun
`782 Sex and the Single Gene
`783 Deep Rocks Stir the Mantle Pot
`
`789 Reproductive Behavior and Health in Consanguineous Marriages: A. H . BITTLES,
`W. M. MAsoN, J. GREENE, N. A. RAo
`795 Neutron Scattering: Progress and Prospects: J.D. AxE
`802 Diversity of G Proteins in Signal Transduction: M. I. SIMoN, M.P. STRATHMANN,
`N. GAUTAM
`
`809 Zinc Finger-DNA Recognition: Crystal Stmcture of a Zif268-DNA Complex at
`2.1 A: N. P. PAVLETICH and C. 0. PABo
`817 A New Cofactor in a Prokaryotic Enzyme: Tryptophan Tryptophylquinone as the
`Redox Prosthetic Group in Methylamine Dehydrogenase: W. S. MciNTIRE,
`D. E. WEMMER, A. CHISTOSERDOV, M. E. LIDSTROM
`
`•
`
`•
`
`SCIENCE (ISSN 0036-8075) Is published weekly on Friday, except the last week In December, by the Am~rican
`Association for the Advancement of Science, 1333 H Street, NW, Washington, DC 20005. Second-class postage
`(publication No. 484460) paid at Washington, DC, and additional mailing offices. Copyright © 1991 by the American
`Association for the Advancement of Science. The title SCIENCE is a registered trademark of the AAAS. Domestic
`Individual membership and subscription (51 Issues): $82 ($50 allocated to subscription). Domestic institutional ·
`subscription (51 issues): $150. Foreign postage extra: Canada $46, other (surface mail) $46, air freight $90. First class,
`airmail, school-year, and student rates on request. Change of address: allow 6 weeks, giving old and new addresses
`and 11-digit account number. Postmaster: Send change of address to Science, P.O. Box 1723, Riverton, NJ 08077.
`Single copy sales: $6.00 per issue prepaid includes surface postage; Guide to Biotechnology Products and
`Instruments, $20. Bulk rates on request. Authorization to photocopy material for internal or personal use under
`circumstances not falling within the fair use provisions of the Copyright Act is granted by AAAS to libraries and other
`users registered with the Copyright Clearance Center (CCC) Transactional Reporting Service, provided that the base
`fee of $1 per copy plus $0.10 per page is paid directly to CCC, 27 Congress Street, Salem, Massachusetls 01970. The
`Identification code for Science Is 0036-8075/83 $1 + .to. Science is indexed in the Reader's Guide to Periodical
`Literature and In several specialized indexes.
`The American Association for the Advancement of Science was founded In 1848 and incorporated in 1874. Its
`objectives are to further the work of scientists, to facilitate cooperation among them, to foster scientific freedom and
`responsibility, to Improve the effectiveness of science in the promotion of human welfare, to advance education in
`science, and to increase public understanding and appreciation of the importance and promise of the methods of
`science in human progress.
`
`752
`
`SCIENCE, VOL. 252
`
`Par Pharm., Inc.
`Exhibit 1029
`Page 002
`
`

`
` 7KLV PDWHULDO PD\ EH SURWHFWHG E\ &RS\ULJKW ODZ 7LWOH  86 &RGH

`
`Our results show that the presence of the
`female-specific tra and the tra-2 products
`promote female-specific splicing of dsx pre(cid:173)
`mRNA and that the 13··nt sequences in the
`female exon and the female-specific acceptor
`sequence participate in regulation of dsx
`expression. The tra and tra-2 products may
`interact directly with the 13-nt sequences in
`the female-specific exon, and such interac(cid:173)
`tions may allow the suboptimal female-spe(cid:173)
`cific polypyrimidine stretch to be recognized
`as a splicing signal, thus resulting in en(cid:173)
`hancement of the use of the female-specific
`acceptor site.
`
`REFERENCES AND NOTES
`
`l. R. Nothiger and M. Steinmann-Zwicky, Trends
`Genet. 1, 209 (1985); T. W. Cline, in Origin and
`Evolution cif Sex, H. 0. Halvorson and A. Monroy,
`Eds. (Liss, New York, 1985), pp. 301-327; B. S.
`Baker, Nature 340, 521 (1989).
`2. B. S. Baker and K. A. Ridge, Genetics 94, 383
`(1980).
`3. B. S. Baker and M. F. Wolfner, Genes Dev. 2, 477
`(1988); K. C. Burtis and B. S. Baker, Cell 56, 997
`(1989).
`4. R. N. Nagoshi, M. McKeown, K. C. Burtis, J. M.
`Belote, B. S. Baker, Cell 53, 229 (1988).
`5. M. McKeown, J. M. Belote, R. T. Boggs, ibid., p.
`887; B. A. Sosnowski, J. M. Belote, M. McKeown,
`ibid. 58, 449 (1989).
`6. K. Inoue, K. Hoshijima, H. Sakamoto, Y. Shimura,
`Nature 344, 461 (1990).
`7. T. Schupbach, Dev. Bioi. 89, 117 (1982); J. M.
`Belote and B.S. Baker, Proc. Nat/. Acad. Sci. U.S.A.
`79, 1568 (1982); Dev. Bioi. 95, 512 (1983).
`8. H. Amrein, M. Gorman, R. Nothiger, Cell 55,
`1025 (1988); T. J. Goralski, J.-E. Edstrom, B. S.
`Baker, ibid. 56, lOll (1989).
`9. C. C. Query, R. C. Bentley, J.D. Keene, ibid. 57, 89
`(1989); I. W. Mattaj, ibid., p. l.
`10. J, M. Belote, M. McKeown, R. T. Boggs, R.
`Ohkawa, B. A. Sosnowski, Dev. Genet. 10, 143
`(1989).
`ll. The region from and including the entire third exon
`to the Pvu II site located 1284 bp downstrean1 of the
`female acceptor site, and the region from the Ace I
`site located 250 bp upstream of the male acceptor
`site to the site located 64 bp downstream of the
`donor site of tl1e fifth exon, were joined and inserted
`into the copia vector.
`12. M. McKeown, J. M. Belote, R. T. Boggs, Cell 53,
`887 (1988).
`13. K. Hoshijima et a/., unpublished observations.
`14. R. N. Nagoshi and B. S. Baker, Genes Dev. 4, 89
`(1990).
`15. The dsx fragment that extends from the third exon to
`1128 bp downstream of the female acceptor site and
`which excludes tl1e polyadenylation signal (Af) was
`fused to the _fiz fragment that contains a portion of
`the intron and the following second exon {corre(cid:173)
`sponding to bases 825 to 2534 of the published
`sequence [A. Laughon and M.P. Scort, Nature 310,
`25 (1984)]}. The resulting fragment was inserted
`into the copia vector.
`16. The region from the third exon (138 bp) to the site
`48 bp downstream of the donor site of the third
`exon, and the region from the site 250 bp upstream
`of the male acceptor site to the site 64 bp down(cid:173)
`stream of the donor site of the fifth exon, were
`joined and inserted into the copia vector.
`17. The copia-dsx deletion mutants were constmcted as
`follows:
`the regions between 345 to 460 bp
`(Rl-5·6), 234 to 459 bp (R5·6), 190 to 480 bp
`(R6), 344 to 599 bp (R1), or 234 to 599 bp (RO)
`downstream of the female acceptor site were deleted
`from copia-dsx, and Kpn I linkers were inserted. A
`polymerase chain reaction (PCR) fragment tl1at
`contained tl1e region 268 to 627 bp downstream of
`the female-specific acceptor site was inserted at the
`Kpn I linker of the RO constmct in the correct
`
`836
`
`orientation ( SR) or in the opposite orientation
`(ASR). PCR was performed essentially as described
`[R. K. Saiki eta/., Science 239,487 (1988)].
`18. 'M. R. Green,A1111t1. Rev. Genet. 20, 671 (1986).
`19. Oligonucleotide-directed mutagenesis was per(cid:173)
`formed essentially as described [M. J. Zoller and M.
`Smitl1, Methods Enzymol. 100, 468 (1983)].
`20. The region 340 to 1128 bp downstream of the
`female acceptor site was deleted from copia-dtz,
`
`copia-dtz(Pyl8), and copia-dtz(Pyl3). Pre·mRNA
`expressed from the deletion construct of copia-dtz
`was spliced at the _fiz acceptor site even in the
`presence of the Ira and lra-2 products in Kc cells.
`21. We thank M. McKeown for Ira eDNA and H. Amrein
`tra-2 eDNA. Supported by Grant-in-Aid
`for
`62065009 for specially promoted research from the
`Ministry of Education, Science and Culture ofJ a pan.
`l November 1990; accepted l March 1991
`
`Solution Structure of FKBP, a Rotamase Enzyme and
`Receptor for FI(506 and Rapamycin
`STEPHEN W. MICHNICK, MICHAEL K. ROSEN, THOMAS J. WANDLESS,
`MARTIN KARPLUS, * STUART L. SCHREIBER*
`
`Immunophilins, when complexed to immunosuppressive ligands, appear to inhibit
`signal transduction pathways that result in exocytosis and transcription. The solution
`structure of one of these, the human FK506 and rapamycin binding protein (FKBP),
`has been determined by nuclear magnetic resonance (NMR). FKBP has a previously
`unobserved antiparallel 13-sheet folding topology that results in a novel loop crossing
`and produces a large cavity lined by a conserved array of aromatic residues; this cavity
`serves as the rotamase active site and drug-binding pocket. There are other significant
`structural features (such as a protruding positively charged loop and an apparendy
`flexible loop) that may be involved in the biological activity of FKBP.
`
`F KBP IS A SOLUBLE, CYTOSOLIC RE(cid:173)
`
`ceptor (1, 2) for the immunosuppres(cid:173)
`sants FK506 and rapamycin (3). Both
`FKBP and cyclophilin (4-6), which is a
`receptor for the immunosuppressant cyclo(cid:173)
`sporin A (CsA), catalyze the interconversion
`of cis- and trans-rotamers of the peptidyl(cid:173)
`prolyl amide bond of peptide and protein
`substrates. These rotamases are inhibited by
`their respective immunosuppressive ligands.
`Mechanistic studies suggest that a complex of
`immunophilin (immunosuppressant binding
`protein) and ligand interferes with the intracel(cid:173)
`lular transport of proteins involved in signal
`transduction pathways associated with both
`exocytosis (7) and transcription (3, 8).
`In this report we present the solution
`structure of human FKBP obtained by nu(cid:173)
`clear Overhauser effect (NOE)-restrained
`molecular dynamics (rMD) simulations (9).
`The NMR structures satisfYing the NOB
`and empirical energy function restraints
`have backbone root-mean-square deviations
`(RMSDs) from the refined average structure
`in the range of 0.80 to 1.4 A for the 13
`strands, 0.19 to 0.40 A for the a helix, and
`1.02 A to 1.72 A for all residues except 83
`to 90 (see below). Many side chains, partic(cid:173)
`ularly aromatics, are well defined. FKBP has
`a novel folding topology in .that two loops
`that connect the strands of an anti parallel 13
`sheet cross one another. Hydrophobic side
`
`Department of Chemistry, Harvard University, Cam(cid:173)
`bridge, MA 02138.
`
`*To whom correspondence should be addressed.
`
`chains in the core of the protein form a
`large, deep pocket that includes the rota(cid:173)
`mase active site and the drug-binding site.
`The structure of the binding site appears to
`be highly conserved in related FK506- and
`rapamycin-binding proteins.
`Sequence-specific assignments of 92% of
`the observable 1 H resonances in FKBP have
`been made by use of a combination of
`homonuclear and heteronuclear two-dimen(cid:173)
`sional NMR techniques as reported earlier
`(10). Structural restraints for the dynamics
`simulations were obtained through empiri(cid:173)
`cal calibration of cross-peak magnitudes in
`nuclear Overhauser effect spectroscopy
`(NOESY) spectra recorded with mixing times
`
`107
`
`Fig. 1. a-Carbon ribbon drawing of human
`FKBP; the five-stranded 13 sheet, a helix, and
`connecting loops are indicated, as well as the
`COOH- and NH2 -termini and certain residues of
`interest.
`
`SCIENCE, VOL. 252
`
`Par Pharm., Inc.
`Exhibit 1029
`Page 003
`
`

`
`Fig. 2. (A) The a-carbon traces of 13 structures
`generated by restrained molecular dynamics are
`shown in blue. (SA)ref> which includes side chains
`of aromatic residues in the drug-binding pocket,
`is shown as the heavy line. Aromatic side chains
`are color-coded: Trp, yellow; Phe, orange; and
`Tyr, green. The NH2 - and COOH-termini are
`indicated with green and red dot surfaces, respec(cid:173)
`tively. (B) (SA),cr, showing location of the ligand
`binding site formed by the 13 sheet and the a helix;
`certain residues are numbered. (C) Expanded
`view of (SA)ref> showing crossing of the loops
`cmmecting the first and fourth (relevant residues
`in orange) and the fifth and second (relevant
`residues in yellow) strands of the 13 sheet; known
`interstrand hydrogen bonds are indicated. Rele(cid:173)
`vant residues in the third strand are shown in
`green. (D) Hydrophobic residues in the drug(cid:173)
`binding pocket of (SA),er· Side chains are color(cid:173)
`coded as in (A), with additional aliphatic residues
`in purple.
`
`of 50, 100, 150, and 200 ms versus known
`distances in regular secondary structural el(cid:173)
`ements (11 ). Of particular use in unambig(cid:173)
`uously determining long-range NOEs were
`two FKBP samples biosynthetically deuter(cid:173)
`ated at the methyl protons of Leu and Ile
`and of Val and Ile (12, 13). A total of 860
`NOB-derived distance constraints was used
`in the simulations. In addition, 43 Xi dihe(cid:173)
`dral angle restraints (in the range ±60° or
`± 120°) and 44 backbone<!> angle restraints (in
`the range ± 60°, ± 50°, or ± 40°) were used; the
`angle constraints are based on analysis of cou(cid:173)
`pling constants and cross-peak magnitudes
`measured in correlated spectroscopy (COSY)
`spectra, and on NOB data (14). In 32 cases, Xi
`could be restricted to a ±60° range, allowing
`stereospecific assignment of side chain protons
`based on intraresidue NOEs from NH and
`CaR. Hydrogen bond constraints were used
`for 25 slowly exchanging amide protons. Sev(cid:173)
`enty-nine NOEs, six hydrogen bonds, and six
`backbone dihedral angles were determined in
`an iterative marmer based on unrefined, re(cid:173)
`strained structures. The rMD simulations
`were carried out by using a simulated anneal(cid:173)
`ing protocol with the program X-PLOR (9).
`Statistics indicative of the accuracy and preci(cid:173)
`sion of the experimentally determined struc(cid:173)
`ture of FKBP and a description of the proto-
`
`REPORTS
`
`837
`
`10 MAY 1991
`
`Par Pharm., Inc.
`Exhibit 1029
`Page 004
`
`

`
`col used to generate these structures are
`provided in Table l.
`The solution structure of FKBP (Figs. 1
`and 2) is characterized by a large am(cid:173)
`phiphilic, antiparallel five-stranded ~ sheet
`with +3, + 1, -3, + 1 topology (15). The
`strands of the sheet are composed of resi(cid:173)
`dues 1 to 7, 20 to 29, 46 to 49, 7l to 77,
`and 96 to 107. An amphiphilic a helix,
`formed from residues 59 to 65, packs
`against the hydrophobic face of the sheet at
`an angle of 60° with respect to the long axis.
`The helix is tethered to the fifth and second
`strands of the sheet by nine- and five-residue
`loops, respectively. The sheet has a right(cid:173)
`handed twist and wraps around the helix to
`form a well-ordered hydrophobic core (Fig.
`1); this structure is in accord with a large
`number of long-range side chain NOE in(cid:173)
`teractions. Backbone hydrogen-bond pro(cid:173)
`pensities are satisfied for the ~ sheet by
`interstrand amide-carbonyl contacts and for the
`a helix by interresidue amide-carbonyl i, i + 3
`contacts. There are no side chain hydrogen
`bonds between the helix and the sheet, indicat(cid:173)
`ing stabilization of these structures through
`hydrophobic (van der Waals) interactions. The
`loops connecting the ~ strands contain second(cid:173)
`ary structural elements (including several ~
`turns) that satisfY some of the backbone hydro(cid:173)
`gen bond propensities. The loops are well
`defined by medium- and long-range NOE con(cid:173)
`tacts except for two regions, residues 37 to 43
`and 83 to 90 (see Fig. 2, A and B).
`A notable feature of FKBP resulting from
`the + 3, + 1, -3, + l topology of the ~ sheet is
`a topological crossing of the loops Ser8-Gly19
`and Leu50-Gln70. A view of this region of the
`protein is shown in Fig. 2C. Although crossing
`topologies have been obsetved in proteins con(cid:173)
`taining parallel ~ sheets (16), they were pre(cid:173)
`sumed to be forbidden in antiparallel sheets
`(17). The absence of loop crossings has been
`attributed to the difficulties of obtaining effi(cid:173)
`cient side chain packing, of satisfYing the hy(cid:173)
`drogen bond propensities of the backbone
`amides of both segments, and of describing a
`simple folding pathway (18). In FKBP, the
`structure of the crossing segments is deter(cid:173)
`mined by NOEs including Thr14-Ser67, Glyl2-
`Ser67 Arg13-Ser67 Pro16-Val68 and Pro16-
`Leu1~6. There are ~an der Waal~ contacts be(cid:173)
`tween the side chains of Pro16 and Leu106,
`Val68 and Leu103, and Thr14 and Val68. The
`hydrogen-bonding propensities of many resi(cid:173)
`dues in the crossing region (Pro9, Asp11
`Thr14, Met66, Ser67, and Val68) are satisfied
`through backbone-backbone and backbone(cid:173)
`side chain interactions. All amide protons in
`the inner strand and two amide protons in the
`outer strand (Lys17 and Gln20) exchange slow(cid:173)
`ly when the protein is dissolved in D 20; this
`result is indicative of hydrogen bonds stabiliz(cid:173)
`ing this topology.
`
`,
`
`838
`
`In a preliminary study of the FKBP(cid:173)
`FK506 and FKBP-rapamycin complexes we
`noted NOEs from the indole ring of Trp59
`and several other unidentified aromatic pro(cid:173)
`tons to the pipicolinyl ring of the bound
`drugs (13). Based on the solution conforma(cid:173)
`tion of FKBP, it was possible to define the
`binding region as an extensive aromatic clus(cid:173)
`ter composed of Tyr26 Phe46 Phe48
`Trp59, Tyr82, and Phe99: These' residue~
`pack together with a number of aliphatic
`residues to form a large, well-defined hydro(cid:173)
`phobic core (Fig. 2D). Thus, FK506 and
`rapamycin bind in the hydrophobic pocket
`that consists of a twisted and curved anti par(cid:173)
`allel ~-sheet platform with walls formed by
`an a helix and a long loop (Fig. 2B). The
`location and detailed structure of the bind(cid:173)
`ing site has been confirmed by the subse(cid:173)
`quent x-ray structure of the FKBP-FK506
`complex (19). The architecture of the bind(cid:173)
`ing site, whose natural ligands are not
`
`known but may include peptides, is very
`different from those formed by ~ barrels in a
`number of proteins that bind hydrophobic
`ligands [such as P2 myelin protein (20) and
`bilin binding protein (21)]. However, al(cid:173)
`though the overall structures are very differ(cid:173)
`ent, the FKBP binding site has elements in
`common with that of the class I major
`histocompatibility complex (MHC) glyco(cid:173)
`protein HLA-A2 (22), which has a flatter
`antiparallel ~-sheet platform with walls
`formed by two long a helices. Peptide seg(cid:173)
`ments that form loops at the open end of the
`pocket, specifically, Asp37 to Asn43 and
`Gly82 to Ile90, are not well defined (see Fig.
`2, A and B). The lack of long-range NOEs
`in both segments coupled with previous
`evidence of conformational exchange in the
`second (10) indicate that they may be flexi(cid:173)
`ble in solution. A comparison of 1 H and
`15N chemical shifts obtained from single(cid:173)
`quantum coherence (SQC) spectra of 15N-
`
`Table 1. Structural and energetic statistics for FKBP. Structure determination was achieved with a
`simulated annealing protocol consisting of three stages: (i) a conformational search phase; (ii) an
`annealing phase; and (iii) a refinement phase (9, 30). Numbers in parentheses are the number of
`restraints in each class or the number of bonds, angles, and dihedrals in the structure geometry
`statistics. SA; is the ith structure obtained by the protocol given above. The SA; column gives the
`average and standard deviations for the indicated variables obtained from the 21 structures with the
`lowest empirical energies and residual violations of experimental restraints. (SA),.r represents the
`average structure of SA; least-square fit to each other including all atoms (except for residues 83 to
`90) and refined with 1000 steps of steepest-descent energy minimization. The RMSDs are from the
`upper or lower bounds of the distance restraints; none of the structures showed deviations greater
`than 0.25 A. Restraints were classified into the following categories based on strong, medium, and
`weak NOEs (11): backbone, 2.5 ± 0.5 A, 2.75 ± 0.75 A, 3.5 ± 1.5 A; side chain, 2.5 ± 0.5 A,
`3.0 ± 1.0 A, 3.5 ± 1.5 A; 0.5 A was added to the upper limits for distances involving methyl
`protons. Average RMSDs and standard deviations of the final structures SA; against the refined
`average structure (SA),.r· For [3 sheet: backbone, 1.01 ± 0.16; all atoms, 1.92 ± 0.14. For ex helix:
`backbone, 0.31 ± 0.07; all atoms, 1.05 ± 0.16. For all atoms except residues 83 to 90: backbone,
`1.45 ± 0.20; all atoms, 2.49 ± 0.17.
`
`Parameter
`
`RMSDsftotll experimellfal distance restrai11ts (A)
`(910)
`0.024 ±
`
`(246)
`(254)
`(39)
`(146)
`
`(12)
`(5)
`(25)
`(133)
`(50)
`
`0.011 ±
`0.024 ±
`0.041 ±
`0.031 ±
`
`0.008 ±
`0.012 ±
`0.018 ±
`0.023 ±
`0.034 ±
`
`Total
`Peptide backbone restraints
`Intraresidue
`Interresidue sequential (li-jl = 1)
`Interresidue short-range (li-jl ,.; 5)
`Interresidue long-range (li-jl > 5)
`Side-chain restraints
`Intraresidue
`Interresidue sequential (li-jl = 1)
`Interresidue short-range (li-jl s 5)
`Interresidue long-range (li-jl > 5)
`Hydrogen-bond restraints*
`Deviations from idealized geometryt
`Bonds (A)
`Angles (degrees)
`Imp ropers (degrees)
`
`(SA),. r
`
`0.008
`
`0.022
`0.008
`0.021
`0.051
`
`0.024
`0.003
`0.000
`0.020
`0.037
`
`0.002
`
`0.003
`0.003
`0.008
`0.004
`
`0.010
`0.018
`0.008
`0.004
`0.008
`
`0.000
`0.064
`0.030
`
`0.013
`3.240
`0.490
`
`SCIENCE, VOL. 252
`
`Etotal
`Ebond
`Bangle
`Edih~dral
`Eimpro per
`Evdw
`
`0.013 ±
`(1682)
`3.360 ±
`(3047)
`0.460 ±
`(498)
`Potetltial enetgy statistics (kcal/mol)
`± 120
`-2280.0
`-2170.0

`3.1
`47.8
`49.9
`± 20
`486.0
`652.0
`± 18
`512.0
`532.0
`1.8
`15.8
`16.5

`± 15
`-358.0
`-336.0
`-3200.0
`± 120
`-2920.0
`Eelectrosratic
`1.7
`5.9
`5.6

`Echide
`3.9
`22.3
`27.0

`ENOE
`*Backbone hydrogen bond restraints were assigned to ranges 'NH- O = 1.9 ± 0.5 A and ' N -o = 2.8 ± 0.5
`A.
`tidealized geometries based on CHARMM parameters (31) .
`
`Par Pharm., Inc.
`Exhibit 1029
`Page 005
`
`

`
`labeled FKBP and the 15N-labeled FKBP(cid:173)
`FK506 complex suggests that significant
`changes occur in these loop regions follow(cid:173)
`ing drug binding. Thus, the distinct inhibi(cid:173)
`tory effects that result from FK506 and
`rapamycin binding ( 8) may involve their
`influence on the geometry of these loops.
`We have recently provided evidence sug(cid:173)
`gesting that the mechanism of rotamase
`catalysis is due to noncovalent stabilization
`of a twisted amide in the transition state of
`the reaction (23, 24), rather than formation
`of a covalent tetrahedral intermediate. A
`similar mechanism has been proposed for
`the rotamase cyclophilin (25, 26). All Lys,
`Ser, and Thr side chains in FKBP are direct(cid:173)
`ed away from the active site, and the Ca of
`Cys22 is ll A from that ofTrp59 toward the
`narrow end of the molecule. The pipecolinyl
`ring ofFK506, which contacts Trp59
`, prob(cid:173)
`ably mimics the proline ring of a natural
`peptide substrate that is subject to rotamase
`catalysis. Thus, the aforementioned residues
`are too far from the active site to add to the
`peptidyl-prolyl amide carbonyl and facili(cid:173)
`tate rotation about the C-N bond. Site(cid:173)
`directed mutagenesis is being used to deter(cid:173)
`mine the role of the tyrosines and other key
`residues found in the active site (Fig. 2D).
`Several higher molecular weight FK506-
`and rapamycin-binding proteins have re(cid:173)
`cently been reported (27). The immunophil(cid:173)
`ins of molecular weight 13,000 and 27,000
`contain FKBP-like domains of -llO amino
`acids that share high sequence identity to
`FKBP (28). Aromatic residues that corre(cid:173)
`, and Phe99
`, Tyr82
`spond to Trp59
`, which
`line the drug-binding pocket, are conserved in
`these proteins and in all FIZBPs identified from
`different organisms to date (8), suggesting that
`the ligand-binding pocket is similar in all FK(cid:173)
`BPs. Thus, the present structure of human
`FIZBP may be relevant to understanding not
`only its own enzymatic and drug-binding
`properties, but those of all members of this
`emerging family of proteins.
`Note added in proif: A report has appeared
`noting the identity of FIZBP to inhibitor-2 of
`protein kinase C (PKCI-2) (29); however, we
`find that FIZBP does not inhibit the kinase
`activity of isolated protein kinase C or protein
`kinase C-mediated events in cells (32).
`
`REFERENCES AND NOTES
`
`l. M. W. Harding et al., Nature 341, 758 (1989).
`2. J, J. Siekierka eta/., ibid., p. 755.
`3. B. E. Bierer eta/., Proc. Nat/. Acad. Sci. U.S.A. 87,
`9231 (1990).
`4. R. E. Handschumacher eta/., Science 226, 544 (1984).
`5. G. Fisher eta/., Nature 337, 476 (1989).
`6. N. Takahashi, T. Hayano, M. Suzuki, ibid., p. 473.
`7. T. Hultsch eta/., Proc. Nat/. Acad. Sci. U. S. A., in
`press.
`8. S. L. Schreiber, Science 251, 283 (1991).
`9. A. T. BriingerandM. Karplus,Acc. Chem. Res. 24,54
`(1991) for review; R. Kaptein, E. R. P. Zuiderweg, R.
`M. Sd1eek, R. Boelens, W. F. van Gunsteren, ]. Mol.
`
`10MAY 1991
`
`Bioi. 182,179 (1985); A. T. Btiinger, G. M. Clore, A.
`M. Gronenborn, M. Katpllh,, Proc. Nat/. Acad. Sci.
`U.S.A. 83, 3801 (1986); M. Nilges, G. M. Clore, A.
`M. Gronenborn, FEBS Lett. 229, 317 (1988); M.
`Nilges, in Computational Aspeds qfthe Study q[Bio/ogical
`Macromolecules by NMR, J, C. Hoch, Ed. (Plenum,
`New Y ark, in press); A. T. Briinger, X-PLOR Manual,
`Version2.1, (Yale University, New Haven 1990).
`10. M. K. Rosen, S. W. Michnick, M. Karplus, S. L.
`Schreiber, Biochemistry, in press.
`11. A. Kumar, G. Wagner, R. R. Ernst, K. Wuthrich, ].
`Am. Chem. Soc. 103, 3654 (1981); M.P. WilliatnSon
`eta/.,]. Mol. Bioi. 182, 295 (1985).
`12. R. F. Standaert, A. Galat, G. L. Verdine, S. L.
`Schreiber, Nature 346, 671 (1990).
`13. T. J. Wandless, S. W. Michnick, M. K. Rosen, M.
`Karplus, S. L. Schreiber, ]. Am. Clwn. Soc. 113,
`2339 (1991).
`14. A. Pardi, M. Billeter, K. Wuthrich, ]. Mol. Bioi.
`180, 741 (1984); D. Neuhaus, G. Wagner, M.
`Vasak, J. H. R. Kagi, K. Wuthrich, Em.]. Biochem.
`151, 257 (1985); G. Wagner et al.,]. Mol. Bioi.
`196, 611 (1987); E. R. P. Zuiderweg, R. Boelens,
`R. Kaptein, Biopolymers 24, 601 (1985).
`15. J. S. Richardson, Nature 268, 495 (1977).
`16. For example, gyceraldehyde phosphate dehydrogenase
`[D. Moras et al.,]. Bioi. Chem. 250,9137 (1975)].
`17. C. Chothia, Amw. Rev. Biochem. 53, 537 (1984);
`Y. N. Chirgadze,Acla Crystallogr. A43, 405 (1987).
`18. 0. B. Ptitsyn and A. V. Finkelstein, Q. Rev. Bio(cid:173)
`phys. 13, 339 (1980).
`19. G. D. Vm Duyne, R. F. Standaert, P. A. Karplus, S.
`L. Schreiber, J. Clardy, Scieuce, 252, 839 (1991).
`20. T. A. Jones, T. Bergfors, J. Sedzik, T. Unge, EMBO
`]. 7, 1597 (1988).
`21. R. Huber eta/.,]. Mol. Bioi. 198, 499 (1987).
`22. P. J. Bjorkmanel a/., Nature 329,506 (1987); ibid.,
`p. 512.
`23. M. K. Rosen, R. F. Standaert, A. Galat, M. Nakat(cid:173)
`suka, S. L. Schreiber, Scieuce 248, 863 (1990).
`24. M. W. Albers, C. T. Walsh, S. L. Schreiber, ]. Org.
`Chem. 55, 4984 (1990).
`25. J. Liu, M. Albers, C. Chen, S. L. Schreiber, C. T.
`Walsh, Proc. Nat/. Acad. Sci. U.S.A. 87, 2304 (1990).
`26. R. K. Harrison and R. L. Stein, Biochemistry 29,
`1684 (1990).
`27. H. Pretzel al.,]. Am. Chem. Soc. 113, 1409 (1991).
`28. Y.-J. Jin, M. W. Albers, B. E. Bierer, S. L. Schreiber,
`S. J, Burakoff, Proc. Nat/. Acad. Sci. U. S. A., in
`press. A. Galat, W. S. Lane, R. F. Standaert, S. L.
`Schreiber, in preparation.
`29. M.G. Goebl, Cel/64, 1051 (1991).
`30. Starting strucrures for the simulated annealing pro(cid:173)
`tocol consisted of FKBP polypeptide chains with
`random backbone dihedral angles. The conforma(cid:173)
`tional search phase consisted of 20 ps of molecular
`
`dynamics at l 000 K under the influence of a force
`field devised for simulated annealing srudies. A
`quartic repulsion potential was used in the force field
`in place of the standard CHARMM van der Waals
`potential for purposes of computational efficiency.
`The force constant of the repulsive potential (ERE(cid:173)
`PEL) was scaled to 0.002 kcal mol- 1 A - 4 during the
`conformational search to allow atoms to pass freely
`through each other. The distance restraint potential
`target function (ENoE) was a square well with
`harmonic walls at the upper and lower bounds of the
`distance restraints and a harmonic plus linear switch(cid:173)
`ing function at 0.5 A above the upper bound. The
`harmonic force constant was 50 kcal mol- 1 A - 2 and
`the linear component had a slope of 5 kcal mol- 1
`A -l. The purpose of this phase was to obtain an
`unbiased search of conformational space with a force
`field dominated by the experimental target function.
`The annealing phase consisted of two stages. First,
`during a 10-ps interval the slope of the linear com(cid:173)
`ponentofENoE was increased to 50 kcal mol- 1 A- 1
`and the scale of EREPEL was raised to 0.1 kcalmol- 1
`A - 4 . Second, the distance restraint potential was
`made harmonic at both the lower and upper distance
`bounds, experimental dihedral restraints were intro(cid:173)
`duced, the scale of EREPEL was increased to 4.0 kcal
`mol- 1 A -4, md the temperarure was adjusted from
`1000 K to 300 K in steps of 25 K over 2.8 ps. The
`experimental dihedral potential (Ecdihc) was a square
`well with harmonic walls at the upper and lower
`bounds with a force constant of 200 kcal mol- 1
`rad- 2
`. The refinement phase consisted of 1000 steps
`of steepest descent minimization in which the full
`CHARMM force field including electrostatic and
`van der Waals nonbonded terms were used (31).
`Statistics were calculated with the program X-PLOR
`(9). Energy analysis was performed with the stan(cid:173)
`dard CHARMM force field (31).
`31. B. R. Brooks eta/.,]. Comp11t. Chem. 4, 187 (1983).
`32. M. W. Albers eta/., Biomed. Chem. Lett., in press.
`33. Coordinates of the 21 final strucrures and of the mini(cid:173)
`mized average strucrure · will be deposited in the
`Brookhaven Protein Data Bank along with a list of all
`experimental restraints. Supported by the National In(cid:173)
`stirute of General Medical Scien= (GM-38627,
`awarded to S.L.S; GM-30804, awarded to M.K.).
`National Science Foundation predoctoral fellowships to
`M.K.R. and T.J,W. are gratefully acknowledged. We
`thankS. Shambayati for pointing out the novelty of the
`loop crossing topology in FKBP. NMR spectra were
`obtained through the auspices of the Harvard Univer(cid:173)
`sity Department of Chemistry Instrumentation Center,
`which was supported by NlH grant 1-Sl0-RR04870
`and NSF grant CHE 88-14019.
`
`29 January 1991; accepted 1 April1991
`
`Atomic Structure of FI<BP-FI(506, an
`Immunophilin-Immunosuppressant Complex
`GREGORY D. VAN DUYNE, ROBERT F. STANDAERT,
`P. ANDREW KARPLUS, STUART L. SCHREIBER,* JON CLARDY*
`
`The structure of the human FK506 binding protein (FKBP), complexed with the immu(cid:173)
`nosuppressant FK506, has been determined to 1.7 angstroms resolution by x-ray crystal(cid:173)
`lography. The conformation of the protein changes little upon complexation, but the
`conformation ofFK506 is markedly different in the bound and unbound forms. The drug's
`association with the protein involves five hydrogen bonds, a hydrophobic binding pocket
`lined with conserved aromatic residues, and an unusual carbonyl binding pocket. The nature
`of this complex has implications for the mechanism of rotarnase catalysis and for the
`biological actions of FK506 and rapamycin.
`
`I N AN ACCOMPANYING REPORT (1), Tim
`
`function of FIZBP (2, 3) was discussed,
`and its structure, determined by nuclear
`
`Overhauser effect (NO E)-restrained molecular
`dynamics, was described. After this structure
`had been determined, experiments were

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket